A5076613880- Metabolomics and Mass Spectrometry Studies
- Mast cells and histamine
- Advanced Chemical Sensor Technologies
- Microfluidic and Capillary Electrophoresis Applications
- Chronic Myeloid Leukemia Treatments
- Nanofabrication and Lithography Techniques
- Cholinesterase and Neurodegenerative Diseases
- Gastric Cancer Management and Outcomes
- PI3K/AKT/mTOR signaling in cancer
- Spectroscopy Techniques in Biomedical and Chemical Research
- Asthma and respiratory diseases
- Amyotrophic Lateral Sclerosis Research
- Lung Cancer Treatments and Mutations
- Isotope Analysis in Ecology
- HER2/EGFR in Cancer Research
- Neurogenetic and Muscular Disorders Research
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Urticaria and Related Conditions
- Alzheimer's disease research and treatments
- Electrowetting and Microfluidic Technologies
- Acute Myeloid Leukemia Research
- Dermatology and Skin Diseases
- Advanced Breast Cancer Therapies
- Histone Deacetylase Inhibitors Research
AB Science (France)
2012-2024
Jena University Hospital
2022
Centre Hospitalier Universitaire de Lille
2022
University of Girona
2022
Institut d'Investigació Biomèdica de Girona
2022
Hospital Arnau de Vilanova
2022
Inserm
2022
Université de Lille
2022
Hospital Universitari de Girona Doctor Josep Trueta
2022
Sorbonne Université
2017
The stem cell factor receptor, KIT, is a target for the treatment of cancer, mastocytosis, and inflammatory diseases. Here, we characterise in vitro vivo profiles masitinib (AB1010), novel phenylaminothiazole-type tyrosine kinase inhibitor that targets KIT.In vitro, had greater activity selectivity against KIT than imatinib, inhibiting recombinant human wild-type with an half inhibitory concentration (IC(50)) 200+/-40 nM blocking factor-induced proliferation phosphorylation IC(50) 150+/-80...
Objective: To assess masitinib in the treatment of ALS. Methods: Double-blind study, randomly assigning 394 patients (1:1:1) to receive riluzole (100 mg/d) plus placebo or at 4.5 3.0 mg/kg/d. Following a blinded transition from phase 2 2/3, prospectively defined two-tiered design was implemented based on ALSFRS-R progression rate disease-onset baseline (ΔFS). This approach selects more homogeneous primary efficacy population (“Normal Progressors”, ΔFS < 1.1 points/month) while concurrently...
Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast and microglia). Study AB09004 evaluated masitinib as adjunct to cholinesterase and/or memantine in patients with mild-to-moderate dementia due probable Alzheimer's disease (AD).Study was a randomized, double-blind, two parallel-group (four-arm), placebo-controlled trial. Patients aged ≥50 years, clinical diagnosis AD Mini-Mental State Examination (MMSE) score 12-25 were...
Masitinib is a selective tyrosine kinase inhibitor, targeting innate immune cells (mast and microglia) that are involved in the pathophysiology of progressive multiple sclerosis (MS). Study AB07002 assessed oral masitinib patients with MS who were progressing but not clinically active.
Abstract Treatment options for patients suffering from indolent forms of mastocytosis remain inadequate with the hyperactivation mast cells responsible many disease's systemic manifestations. Masitinib is a potent and highly selective oral tyrosine kinase inhibitor. A combined inhibition c‐Kit Lyn make it particularly efficient in controlling activity therefore, potential therapeutic benefit mastocytosis. was administered to 25 diagnosed as having or cutaneous related handicap (i.e.,...
BackgroundMasitinib is a selective oral tyrosine–kinase inhibitor. The efficacy and safety of masitinib combined with gemcitabine was compared against single-agent in patients advanced pancreatic ductal adenocarcinoma (PDAC).Patients methodsPatients inoperable, chemotherapy-naïve, PDAC were randomized (1: 1) to receive (1000 mg/m2) combination either (9 mg/kg/day) or placebo. primary endpoint overall survival (OS) the modified intent-to-treat population. Secondary OS analyses aimed...
Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST). was evaluated in patients advanced GIST after imatinib failure or intolerance.
A randomized, placebo-controlled phase III study (AB10015) previously demonstrated that orally administered masitinib (4.5 mg/kg/day) slowed rate of functional decline, with acceptable safety, in amyotrophic lateral sclerosis (ALS) patients having an ALS Functional Rating Scale-revised (ALSFRS-R) progression from disease onset to baseline <1.1 points/month. Here we assess long-term overall survival (OS) data all participants AB10015 and test whether a signal OS is evident enriched patient...
The amyotrophic lateral sclerosis (ALS) functional rating scale-revised (ALSFRS-R) has become the most widely utilized measure of disease severity in patients with ALS, change ALSFRS-R from baseline being a trusted primary outcome ALS clinical trials. This is despite scale having several established limitations, and although alternative scales have been proposed, it unlikely that these will displace foreseeable future. Here, we discuss merits delta FS (ΔFS), slope or rate decline over time,...
Background Tyrosine kinases are attractive targets for pancreatic cancer therapy because several over-expressed, including PDGFRα/β, FAK, Src and Lyn. A critical role of mast cells in the development has also been reported. Masitinib is a tyrosine kinase inhibitor that selectively c-Kit, Lyn, to lesser extent FAK pathway, without inhibiting known toxicities. particularly efficient controlling proliferation, differentiation degranulation cells. This study evaluates therapeutic potential...
Since current treatment options for patients suffering from active rheumatoid arthritis (RA) remain inadequate, especially those unresponsive to disease-modifying antirheumatic drugs (DMARDs), new and improved medication is needed. This study evaluates the safety efficacy of masitinib (AB1010), a potent selective protein tyrosine kinase inhibitor c-KIT, in monotherapy DMARD-refractory RA.This was multicentre, uncontrolled, open-label, randomised, dose-ranging, phase 2a trial. Masitinib...
Most patients with systemic mastocytosis bear mutations in the tyrosine kinase receptor gene c-Kit. Limited treatment options exist for mast cell leukemia, a rare form of associated dire prognosis. Our aim was to investigate c-Kit leukemia and find new this severe mastocytosis.We describe here patient characterized by 42% circulating cells previously unidentified mutation adult mastocytosis: dup(501-502).This treated masitinib, novel inhibitor, dramatic response observed following 3 months...
Masitinib is an oral tyrosine kinase inhibitor that selectively targets mast cell activity and platelet-derived growth factor receptor (PDGFR) signaling, both of which are implicated in various mechanisms asthma pathogenesis.Assessment masitinib as add-on to standard maintenance therapy compared with placebo the treatment corticosteroid-dependent severe asthma.We conducted a randomized (2:1), placebo-controlled study (6 mg/kg/d) adults uncontrolled by high dose inhaled corticosteroids...
This study evaluated the therapeutic potential of masitinib, an oral tyrosine kinase inhibitor with activity against c-Kit and platelet-derived growth factor receptors (PDGFR), to reduce ischemic brain area neurological deficit. Using a well-established filament model stroke in rats, responses treatment masitinib alone or combination recombinant tissue plasminogen activator (rt-PA) were compared those after rt-PA (10 mg/kg intravenously (i.v.)) monotherapy. In both cases, two doses used--25...
Masitinib, a highly selective protein kinase inhibitor, can sensitise gemcitabine-refractory cancer cell lines when used in combination with gemcitabine. Here we report reverse proteomic approach that identifies the target responsible for this sensitisation: deoxycytidine (dCK). as well other inhibitors, such imatinib, interact dCK and provoke an unforeseen conformational-dependent activation of nucleoside kinase, modulating phosphorylation analogue drugs. This phenomenon leads to increase...
Infrared (IR) spectroscopy has previously been established as a means to accurately quantify several serum and urine metabolites, based upon of dry films. The same technique also provided the basis develop certain diagnostic tests, developed in 'metabolomics' spirit. Here, we report on further development an integrated microfluidic-IR technology technique, customized with aim dramatically extending capabilities IR both analytical (metabolomic) applications. By exploiting laminar fluid...
An instrument for automated microcontact printing (microCP) on microscope slides is described. The movement of the stamp, which actuated by a computer controlled pneumatic actuator, precisely guided until it makes contact with substrate. As consequence, absolute position microprinted patterns reproducible over series substrates 1 mum standard deviation. Exchange and stamps quick simple procedure. This possible microprinting adjacent or superimposable patterns, different products, in manner....